Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.

导出 OA

翻译打印收藏纠错

作者： Ping,Hu ^[1] ; Haiqing Isaac,Dai ^[1] ; James,Bourdage ^[2] ; Dongli,Zhou ^[2] ; Ky,Trang ^[2] ; Karey,Kowalski ^[3] ; Carlo,Bello ^[4] ; Jennifer,Hibma ^[4] ; Akash,Khandelwal ^[2] ; Kyra,Cowan ^[2] ; Jennifer,Dong ^[1] ; Karthik,Venkatakrishnan ^[1] ; Wei,Gao ^[1]

作者单位： EMD Serono, Billerica, Massachusetts, USA. ^[1] the healthcare business of Merck KGaA, Darmstadt, Germany. ^[2] Pfizer, La Jolla, California, USA. ^[3] Pfizer, San Diego, California, United States. ^[4]

主题词人类(Humans);癌, Merkel细胞(Carcinoma, Merkel Cell);癌, 移行细胞(Carcinoma, Transitional Cell);皮肤肿瘤(Skin Neoplasms);膀胱肿瘤(Urinary Bladder Neoplasms);临床试验(主题)(Clinical Trials as Topic)

DOI 10.1111/cts.13730

PMID 38411318

发布时间 2024-10-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交